AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling

During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet